Sentence examples for in previously reported phase from inspiring English sources

Afatinib pharmacokinetics were comparable to those observed in previously reported phase I trials.

Treatment with desvenlafaxine 10 mg/day and 50 mg/day was generally safe and well-tolerated, with TEAEs observed in this study comparable to those observed in previously reported phase 3 studies of desvenlafaxine treatment for MDD.

The poorer performance status and more advanced disease status of patients included in this study is also reflected by the 60-day mortality rate of 10% that was higher than in previously reported phase II trials of the same group of authors (Lordick et al, 2005; Lorenzen et al, 2007).

In previously reported phase I/Ib trials, the MTD of erlotinib with cytotoxic agents ranged from 100 mg day−1 (with capecitabine/docetaxel: Trigo et al, 2003; with capecitabine/oxaliplatin: van Cutsem et al, 2003; with docetaxel: Mita et al, 2002) to 150 mg day−1 (with oxaliplatin/5-FU: Jones et al, 2003).

In previously reported phase III clinical studies of docetaxel in combination with capecitabine and of paclitaxel in combination with gemcitabine, the median time to disease progression was 6.1 months for both combination therapy groups, a significantly longer duration than those in the corresponding monotherapy groups.

Here, we report a retrospective analysis evaluating activity, efficacy, and safety of first-line FIr-B/FOx intensive regimen and the prognostic value of extension of metastatic disease [ 4, 5] in fit young-elderly MCRC patients enrolled in a previously reported phase II study [ 1] and in the expanded clinical program proposing first-line FIr-B/FOx treatment.

Present retrospective analysis evaluated consecutive young-elderly patients 65 to 75 years enrolled in a previously reported phase II study [ 1] and in the expanded clinical program proposing first-line FIr-B/FOx treatment.

The intent-to-treat (ITT) population comprised all randomly assigned patients who received at least one injection of exenatide in the previously reported phase of this study (17).

In addition, the previously reported phase I study of pazopanib and lapatinib determined the recommended phase II dose of pazopanib to be 800 mg and of lapatinib to be 1500 mg.

1H NMR linewidth measurements as a function of temperature showed a large decrease in linewidth above 100 °C, attributed here to an increase in mobility in agreement with a previously reported phase transition at ∼110 °C.

The baseline patient characteristics are denoted in supplemental information, Table  1 for the previously reported phase II clinical trial of first-line sorafenib therapy in metastatic RCC [ 13].